Gilead To Become Victim Of Own Success In Japan?
This article was originally published in PharmAsia News
Gilead Sciences is on a roll both globally and in Japan, where two of its key drugs for hepatitis C have been launched this year and the California-based company is planning to roll out other pipeline products, including in oncology. But the rapid sales growth for its HCV products is raising the specter of possible price cuts.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.